The treatment of advanced melanoma has been revolutionised by the advent of immunotherapies inhibiting checkpoints on T cells (e.g., ipilimumab, nivolumab, pembrolizumab) ([@bib8]; [@bib12]; [@bib19]) and inhibition of the mitogen-activated protein kinase (MAPK) pathway with BRAF inhibitors (vemurafenib, dabrafenib, encorafenib alone or in combination with MEK inhibitors (trametinib, cobimetinib)) in patients with BRAF V600-mutant melanoma ([@bib4]; [@bib7]; [@bib11]; [@bib13]). Emerging data suggest that a subset of patients treated with BRAF/MEK inhibitors survive beyond 3 years, and over 20% are progression free at 3 years ([@bib14]). Furthermore, patients who achieved a complete response (CR) had a 3-year survival of \>60% ([@bib14]). Although patients who undergo a CR have a favourable survival, relapses while on treatment occur, with 2 of 7 patients relapsing in one recently published series ([@bib16]).

Unlike many immunotherapy studies, where treatment was continued for a finite period of time (unless there was progression or unacceptable toxicity), all studies of BRAF±MEK inhibitors continued treatment indefinitely (unless there was progression or unacceptable toxicity). The question of whether BRAF-targeted therapy should be continued until progression or whether it can be stopped at an earlier time point without the loss of benefit remains an unanswered question. Such considerations are clinically relevant given the impact that persistent low-grade toxicities can have on patient quality of life and the potential risk of secondary malignancies due to paradoxical activation of the MAP kinase pathway with BRAF inhibitors ([@bib15]). Furthermore, indefinite treatment durations have health economic consequences.

Here we describe the outcomes of a case series of 12 patients who obtained a CR with a BRAF inhibitor alone or in combination with a MEK inhibitor, and subsequently ceased treatment.

Materials and methods
=====================

Patients with BRAF V600-mutant metastatic melanoma treated at three institutions, Melanoma Institute Australia and the Crown Princess Mary Cancer Centre Westmead Hospital, Sydney, Australia, and the National Cancer Institute, Naples, Italy, who achieved a CR after treatment with a BRAF inhibitor alone, or in combination with a MEK inhibitor, and ceased treatment for reasons other than disease progression were identified. The study was approved by individual institution ethics committees. Disease characteristics at the time of treatment initiation, and the timing and reasons for treatment cessation were recorded. In patients who relapsed, disease characteristics and response to subsequent therapy were documented. Progression-free survival (PFS) was determined using the Kaplan--Meier method.

Results
=======

Patients and treatment
----------------------

From October 2009 to October 2015, 12 eligible patients were identified who had been enrolled in clinical trials or received BRAF±MEK inhibitor treatment as part of an expanded access programme. Six patients were male and the median age was 49 years (range 29--62) ([Table 1](#tbl1){ref-type="table"}). In all, 10 (83%) patients had BRAF V600E-mutant melanoma, 9 (75%) had AJCC stage M1c disease and 11 (92%) had normal LDH. Five (42%) patients were treated with BRAF inhibitor monotherapy, whereas seven (58%) patients started with a combination of dabrafenib and trametinib.

All patients stopped treatment because of toxicity, and one (patient 2) ceased treatment because of the diagnosis of a new RAS-mutant pancreatic cancer that was attributed to BRAF inhibitor-induced paradoxical MAPK pathway activation ([@bib3]).

Treatment outcomes
------------------

The median time from treatment initiation to CR was 6.5 months (range 1.6--18.6; [Table 1](#tbl1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). The median duration of treatment in CR was 8 months. The median follow-up after treatment cessation was 16 months (range 2.9--59.5). From the time of treatment initiation the median PFS was 49.2 months, with the landmark 24-month PFS 64.8%.

Patient characteristics at disease recurrence
---------------------------------------------

Six patients (50%) experienced disease recurrence after treatment cessation ([Table 2](#tbl2){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}). In all of the patients who relapsed, disease recurred in original organ sites; three patients also developed metastasis in new organ sites ([Table 2](#tbl2){ref-type="table"}). One patient (patient 6) had refused follow-up before relapse, was not undergoing regular surveillance imaging and represented with symptomatic intracranial disease. Of the other five patients at relapse, four were ECOG 0 and the fifth was ECOG 1, and all had a normal or near normal LDH (\<1.2 times upper limit of normal).

No clinical features either at the time of treatment commencement or cessation were associated with a subsequent relapse ([Table 1](#tbl1){ref-type="table"}). All patients who relapsed had a normal LDH at baseline. Furthermore, there was no difference in the time to CR, length of treatment or the treatment-related toxicities that led to cessation between those who relapsed and those who did not ([Table 1](#tbl1){ref-type="table"}).

The median time from treatment cessation to disease recurrence was 6.6 months (range 1.6--21 months). Of the six patients who relapsed, three subsequently received treatment with a combination of dabrafenib and trametinib, and two had a partial response (patients 4 and 9). The third patient was lost to follow-up (patient 6). The remaining three patients received immunotherapy ([Table 2](#tbl2){ref-type="table"}).

Two patients have died ([Figure 1](#fig1){ref-type="fig"}), the first from pancreatic cancer without evidence of melanoma recurrence (patient 2), and the second (patient 6) from melanoma at ∼8 months after relapse.

Discussion
==========

In this case series of patients with metastatic melanoma who achieved a CR and then ceased BRAF inhibitor-based therapy, we found that half subsequently relapsed, and there were no predictors for disease recurrence. All patients who were under regular clinical review with radiological surveillance were asymptomatic, or only had minor symptoms at relapse. The majority of patients had normal LDH at relapse, and all were suitable for subsequent therapy, including recommencing BRAF/MEK inhibitors with at least two of three responding.

A limitation of this study is the retrospective nature of the analysis, and the small cohort of patients under consideration. However, the multi-institutional experience may help overcome any bias from a single-centre analysis. Furthermore, the clinical characteristics and PFS of the patients included in this series are consistent with those who had undergone a CR in large international studies of dabrafenib in combination with trametinib ([@bib14]), suggesting this is a representative cohort. One important observation from our series is the absence of a correlation between duration of treatment and maintenance of response after that treatment was stopped. For example, one patient who stopped treatment after 5 months is disease free 59 months later. In contrast, another patient who received dabrafenib monotherapy for 60 months relapsed 9.7 months after treatment was stopped. Interestingly, one patient who received vemurafenib for 5.7 months obtained a best response 2.6 months after treatment cessation, and remains disease free with a follow-up of 44.5 months.

Two other publications have recently reported on the cessation of BRAF inhibitor treatment before progression. The first described three patients who experienced durable complete responses with BRAF inhibitor therapy that was then suspended because of toxicity; at a median follow-up of 15 months, none had relapsed. Of particular interest, all had previously been treated with interleukin-2 and ipilimumab ([@bib21]). Consistent with our data, in a retrospective case series, half of the 12 patients who achieved a CR during treatment with a BRAF inhibitor remained disease free, with a median duration of follow-up after treatment discontinuation of 17 months ([@bib20]).

The rate of relapse seen in this and prior series is higher than what is seen with anti-PD1-treated melanoma. In the phase I study of pembrolizumab, 61 patients who achieved a CR stopped therapy. After a median of 10 months off treatment, only two patients (3%) had progressed ([@bib18]).

One hypothesis for disease recurrence after a CR and cessation of treatment may be that micrometastatic disease remains under cytostatic control during treatment, and after treatment cessation this subclinical disease is then able to proliferate. In preclinical models, genetic alterations other than BRAF mutations, such as PTEN loss, are associated with an inability of BRAF inhibitors to induce apoptosis while maintaining their cytostatic effect ([@bib17]). Interpatient heterogeneity of such variables may explain why only a subset of patients relapse. An alternative hypothesis is that immune mechanisms have played a role in those patients who have not recurred ([@bib10]).

The impact of cessation of kinase inhibitors has also been examined in other malignancies. In advanced gastrointestinal stromal tumours (GISTs), the cessation of imatinib, even in patients without residual disease, leads to rapid disease recurrence ([@bib2]). Moreover, the data regarding the need for ongoing treatment with trastuzumab in HER-2-amplified metastatic breast cancer are limited and conflicted, with both relapses and prolonged responses seen ([@bib1]; [@bib6]). Trastuzumab-treated breast cancer may rely on immunological mechanisms via antibody-dependent cell toxicity, not possible with small-molecule inhibitors ([@bib5]).

The patients presented here differ from those described with GIST in that the time from treatment cessation to relapse varied from \<2 months to almost 2 years, suggesting treatment cessation does not result in a rapid expansion of subclinical disease. Given this, it is unknown whether the cessation of treatment increases the likelihood of disease recurrence, as compared with patients in CR who continue treatment, as relapses do occur in patients who have undergone a CR while remaining on treatment ([@bib16]; [@bib14]).

The data presented here may have implications for the potential adjuvant use of BRAF and MEK inhibitors in BRAF-mutant melanoma. In GISTs treated with adjuvant imatinib, an increased rate of recurrences are seen soon after cessation of treatment ([@bib9]). Two adjuvant studies in BRAF V600-mutant melanoma (BRIM-8 (NCT01667419) and COMBI-AD (NCT01682083)) have completed accrual and results are awaited. In both studies patients received 12 months of vemurafenib or dabrafenib/trametinib or placebo, respectively. It remains to be determined whether adjuvant BRAF/MEK inhibition will prevent relapse and be associated with an improved overall survival or only delay relapse with benefit limited to an improvement in relapse- free survival only.

A significant proportion of patients (50% in our case series) who obtain a CR on BRAF±MEK inhibitor therapy have continued prolonged response after cessation. Based on the available data in this and other series, predicting those who will obtain long-term benefit *vs* those who will relapse is not possible. Prospective randomised discontinuation clinical trials with added translational end points may answer the question of who can safely cease treatment. However, recruitment to such a study would be difficult in the current treatment landscape of melanoma. The data presented in this case series should assist clinicians and their patients to make individualised decisions, and patients should remain on treatment until progression or unacceptable toxicity. Importantly the clinical behaviour of all patients who relapsed while undergoing close surveillance including regular imaging suggests treatment interruption is unlikely to be associated with rapid progression leading to death without the ability to institute subsequent treatment.
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###### Patient characteristics

        **Baseline characteristics**                                                                                                                                                                                                        
  ---- ------------------------------ --- ------ --- ------- --- ----------------------------------------- ------------- ------ --------------------------------- ----------------------------------- ----- ------------------------------- ---------------------------------
  1                  61                F   IIIc   N   V600E   2  In transit disease, LN                       CombiDT     7.5                 14.8                Recurrent fevers                     Yes                1.6                              ---
  2                  62                M   M1c    N   V600E   5  Liver, bone, LN, peritoneal                  CombiDT     5.8                  6.9                New pancreatic cancer                No                 ---                15.7[a](#t1-fn2){ref-type="fn"}
  3                  64                M   M1c    N   V600E   3  Bone, LN, right cardiac                    Vemurafenib   1.6                  3.5                RVO, bilateral facial nerve palsy    No                 ---                             59.5
  4                  62                F   IIIc   N   V600E   1  In transit                                 Dabrafenib     7                  53.1                Multiple colonic polyps              Yes                9.7                              ---
  5                  61                M   M1c    N   V600E   4  Adrenal, subcutaneous, peritoneal, lung    Encorafenib   5.4                  3.6                Palmar--plantar keratopathy          Yes                3.5                              ---
  6                  29                M   M1c    N   V600E   4  LN, brain,                                   CombiDT     18.8                 9.4                Drop in LVEF                         Yes   21[b](#t1-fn3){ref-type="fn"}                 ---
  7                  39                F   M1c    N   V600E   3  Liver, spleen, lung                          CombiDT     10.1                18.8                New bronchiectasis                   No                 ---                              2.9
  8                  77                F   M1c    N   V600E   2  Subcutaneous, bone                           CombiDT      13                  2.8                Heart failure                        No                 ---                             22.4
  9                  53                F   M1a    N   V600K   1  LN                                         Vemurafenib   1.8                  5.6                Hyperkeratosis, panniculitis         Yes               14.7                              ---
  10                 45                M   M1c    ↑   V600E   2  LN, liver                                  Vemurafenib   8.4    −2.6[c](#t1-fn4){ref-type="fn"}  Severe skin toxicity                 No                 ---                             45.1
  11                 45                M   M1c    N   V600E   3  Lung, liver, spleen                          CombiDT      6                   9.1                Arthralgia                           No                 ---                              6.8
  12                 44                F   M1c    N   V600K   1  Pancreas                                     CombiDT     2.1                 10.3                Fevers and arthralgia                Yes                2.3                              ---

Abbreviations: CombiDT=combination of dabrafenib/trametinib; CR=complete response; F=female; LDH=lactate dehydrogenase; LN=lymph node; LVEF=left ventricular ejection fraction; M=male; met=metastatic; N=normal (\<upper limit of normal); PD=progressive disease; RVO=retinal vein occlusion.

Death from advanced pancreatic cancer 15.7 months following drug cessation.

Patient 6 was lost to follow-up. Minimal information regarding details of recurrence and death gleaned from correspondence, and date of relapse is an approximation.

Complete response achieved 2.6 months after drug cessation.

###### Patient demographics at relapse and response to subsequent therapy

  **Patient**                    **Treatment**    **Time from drug cessation to progression (months)**  **Site of progression**    **ECOG at progression**   **LDH at progression**  **Subsequent treatment**                 **Subsequent response**   **Length of follow-up post subsequent treatment (months)**  **Outcome**
  ------------------------------ --------------- ------------------------------------------------------ ------------------------- ------------------------- ------------------------ --------------------------------------- ------------------------- ------------------------------------------------------------ -------------
  1                              CombiDT                                  1.6                           Old                                   0                        N             Ipilimumab                                         SD                                         20.5                             Alive
  4                              BRAFi                                    9.7                           Old                                   0                        N             BRAFi/MEKi                                         PR                                         3.2                              Alive
  5                              BRAFi                                    3.5                           Old and new                           0                    1.2 × ULN         Ipilimumab and pembrolizumab                       CR                                          9                               Alive
  6[a](#t2-fn2){ref-type="fn"}   CombiDT                                  ∼21                           Old                                Unknown                  Unknown          BRAFi/MEKi                                       Unknown                                       ∼8                              Died
  9                              BRAFi                                    14.7                          Old and new                           1                    1.1 × ULN         BRAFi/MEKi[b](#t2-fn3){ref-type="fn"}              PR                                          23                              Alive
  12                             CombiDT                                  2.3                           Old and new                           0                        N             Ipilimumab[c](#t2-fn4){ref-type="fn"}              PD                                         8.5                              Alive

Abbreviations: BRAFi=BRAF inhibitor; CombiDT=combination of dabrafenib/trametinib; CR=complete response; ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase; MEKi=MEK inhibitor; N=normal; PD=progressive disease; PR=partial response; SD=stable disease; ULN=upper limit of normal.

Patient 6 was lost to follow-up. Minimal information regarding details of recurrence and death gleaned from correspondence, and date of relapse is an approximation.

Patient 9 was subsequently treated with ipilimumab and then nivolumab.

Patient 12 was subsequently treated with pembrolizumab.
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